We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+21.92%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.44B
AUM Growth
+$302M
Cap. Flow
+$9.92M
Cap. Flow %
0.69%
Top 10 Hldgs %
50.32%
Holding
229
New
57
Increased
37
Reduced
31
Closed
55
Avg Time Held Equity + Options
2.9 quarters
Top 10 Avg Time Held Equity + Options
4.7 quarters
Top 20 Avg Time Held Equity + Options
4.1 quarters
Avg Time Held Equity only
3.1 quarters
Top 10 Avg Time Held Equity only
4.7 quarters
Top 20 Avg Time Held Equity only
4.9 quarters

Top Buys

Rank Stock Value
1
NXTM
NxStage Medical Inc.
NXTM
+$24.7M
2
MDVN
MEDIVATION, INC.
MDVN
+$23.8M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$18.4M
4
STJ
St Jude Medical
STJ
+$16.6M
5
LJPC
La Jolla Pharmaceutical Company
LJPC
+$11.4M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$41.5M
2
HUM icon
Humana
HUM
+$20.1M
3
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$12.4M
4
BAX icon
Baxter International
BAX
+$9.04M
5
XLRN
Acceleron Pharma
XLRN
+$6.5M

Sector Composition

Rank Sector Weight
1 Healthcare 78.68%
2 Miscellaneous 20.64%
3 Consumer Staples 0.52%
4 Consumer Discretionary 0.08%
5 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
SIOX
51
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$6.23M 0.43%
60,625
– –
2015 Q2
4 quarters
ZYNE
52
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
$5.82M 0.4%
849,350
– –
2015 Q3
3 quarters
FWP
53
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$5.66M 0.39%
44,486
+17,872
+67% +$2.41M
2016 Q1
1 quarter
ACAD icon
54
Acadia Pharmaceuticals
ACAD
$3.2B
$5.36M 0.37%
165,240
-90,000
-35% -$3.01M
2014 Q1
9 quarters
SUPN icon
55
Supernus Pharmaceuticals
SUPN
$2.44B
$5.09M 0.35%
250,000
+50,000
+25% +$887K
2016 Q1
1 quarter
FOMX
56
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$5.05M 0.35%
+795,000
New +$5.28M
2016 Q2
0 quarters
CLLS icon
57
Cellectis
CLLS
$111M
$4.88M 0.34%
183,507
+180,511
+6,025% +$5.29M
2015 Q1
5 quarters
ARCT icon
58
Arcturus Therapeutics
ARCT
$345M
$4.62M 0.32%
146,896
– –
2015 Q4
2 quarters
NEOS
59
DELISTED
Neos Therapeutics, Inc
NEOS
$4.61M 0.32%
626,876
+526,876
+527% +$5.03M
2015 Q3
3 quarters
ANTH
60
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$4.61M 0.32%
186,520
– –
2013 Q2
12 quarters
OTLK icon
61
Outlook Therapeutics
OTLK
$139M
$4.46M 0.31%
+8,205
New +$4.89M
2016 Q2
0 quarters
CLSD icon
62
DELISTED
Clearside Biomedical
CLSD
$4.45M 0.31%
+42,321
New +$4.44M
2016 Q2
0 quarters
ASMB icon
63
Assembly Biosciences
ASMB
$421M
$4.41M 0.31%
66,250
– –
2015 Q1
5 quarters
NDRM
64
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$4.39M 0.3%
270,000
– –
2014 Q4
6 quarters
TSRO
65
PUT
DELISTED
TESARO, Inc.
TSRO
$4.2M 0.29%
+50,000
New +$2.23M
2016 Q2
0 quarters
ABEO icon
66
Abeona Therapeutics
ABEO
$262M
$4.16M 0.29%
70,515
– –
2014 Q4
6 quarters
AGRX
67
DELISTED
Agile Therapeutics
AGRX
$3.91M 0.27%
257
+169
+192% +$2.31M
2016 Q1
1 quarter
ANIP icon
68
ANI Pharmaceuticals
ANIP
$1.63B
$3.75M 0.26%
67,161
-46,899
-41% -$2.28M
2014 Q4
6 quarters
ELDN icon
69
Eledon Pharmaceuticals
ELDN
$190M
$3.64M 0.25%
4,081
+1,085
+36% +$1.2M
2014 Q3
7 quarters
GNVC
70
DELISTED
GenVec, Inc.
GNVC
$3.45M 0.24%
60,664
– –
2014 Q1
9 quarters
CASC
71
DELISTED
Cascadian Therapeutics, Inc.
CASC
$3.22M 0.22%
569,020
– –
2013 Q3
11 quarters
KA icon
72
DELISTED
Kineta, Inc. Common Stock
KA
$3.03M 0.21%
1,786
– –
2016 Q1
1 quarter
AVEO
73
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$2.99M 0.21%
+310,881
New +$3M
2016 Q2
0 quarters
INNL
74
DELISTED
Innocoll Holdings plc Ordinary Shares
INNL
$2.81M 0.19%
+560,000
New +$4.59M
2016 Q2
0 quarters
CEMP
75
DELISTED
Cempra, Inc.
CEMP
$2.8M 0.19%
170,000
+20,000
+13% +$353K
2016 Q1
1 quarter
1 2
3
4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q2 2016 Portfolio in Review

As of Q2 2016, Perceptive Advisors held 229 positions worth $1.44B, up 27% from $1.14B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Perceptive Advisors's Q2 2016 filing shows 57 new, 37 increased, 31 reduced and 55 closed positions. Its largest new stake was NxStage Medical Inc.: 1,382,410 shares worth $30M. The largest sale was Allergan plc, an estimated $41.5M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 93% a quarter earlier, followed by Miscellaneous and Consumer Staples.

  • Perceptive Advisors's largest Q2 2016 buy was NxStage Medical Inc.: 1,382,410 shares worth $30M.
  • Perceptive Advisors added most to MEDIVATION, INC. in Q2 2016, an estimated $23.8M increase.
  • Perceptive Advisors's biggest Q2 2016 reduction was Five Prime Therapeutics, Inc., cutting an estimated $12.4M.
  • Perceptive Advisors fully exited Allergan plc in Q2 2016, selling an estimated $41.5M.
  • Perceptive Advisors's ten largest holdings make up 50% of its $1.44B portfolio in Q2 2016.
  • Perceptive Advisors opened 57 new positions and closed 55 in Q2 2016.
  • Perceptive Advisors's portfolio value rose 27% quarter-over-quarter to $1.44B.

Based on Perceptive Advisors's 13F filing for Q2 2016, filed 11 Aug 2016.